It was confirmed by quantitative analysis with Image J that comparing with control group, the exogenous VEGF-C treatment significantly promoted the lymphatic angiogenesis within the HCC tumor sites (Fig. 5g, p < 0.01). The gene discussed is VEGFC; the disease is neoplasm.